We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Series of studies to observe signals of inflammation and TNF-alpha levels in patients taking GLP-1s including Wegovy® or Ozempic® Lean body mass accounts for up to 40% of weight loss from GLP-1...
Set to begin larger Phase 2b study in sarcopenia and new trial in GLP-1-induced sarcopenia and frailty Transformative potential for novel TNF-alpha inhibitor drug: Estimated $40 billion TNF...
Fully funded study to evaluate Wegovy and Ozempic patients at risk for increased inflammation associated with sarcopenic muscle deterioration Collaboration partner to use AI and machine learning...
A Maryland-based biotech company found very early success during Tuesday’s premarket hours a day after the company reported statistically significant phase 2a results for To read the full...
Based on successful Phase 2a data, Company set to initiate Phase 2b sarcopenia study in early 2025; currently securing centers of excellence to begin enrollment First oral TNF-α inhibitor, if...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.317239 | -27.586 | 1.15 | 1.3799 | 0.81 | 777193 | 1.06820746 | CS |
4 | -0.307239 | -26.9507894737 | 1.14 | 1.52 | 0.81 | 436788 | 1.20474831 | CS |
12 | -0.467239 | -35.9414615385 | 1.3 | 1.64 | 0.81 | 239895 | 1.28135869 | CS |
26 | -1.117239 | -57.2943076923 | 1.95 | 2.16 | 0.81 | 127824 | 1.36351712 | CS |
52 | -1.167239 | -58.36195 | 2 | 2.16 | 0.81 | 127067 | 1.37900034 | CS |
156 | -1.167239 | -58.36195 | 2 | 2.16 | 0.81 | 127067 | 1.37900034 | CS |
260 | -1.167239 | -58.36195 | 2 | 2.16 | 0.81 | 127067 | 1.37900034 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions